HC Wainwright & Co. Reiterates Buy on Zentalis Pharmaceuticals, Maintains $10 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado has reiterated a Buy rating on Zentalis Pharmaceuticals (NASDAQ: ZNTL) and maintained a price target of $10 for the stock.